Biotronik launches MRI-approved Evia HF-T pacemaker in Europe

Biotronik has announced the European launch of Evia HF-T, the first cardiac resynchronisation therapy (CRT) pacemaker series approved for use in an MRI environment.

The new device will allow CRT pacemaker patients to benefit from MRI scanning for the first time, meaning they can be diagnosed for problems such as brain tumours and arthritis without fear of interference with their pacemakers.

In addition, the Evia HF-T range is compatible with the Biotronik Home Monitoring system, which offers a number of remote patient management options, while additional data can be provided by the Heart Failure Monitor system.

The launch of the new pacemaker series completes the line-up for the company's advanced bradycardia product portfolio.

Christoph Bohmer, managing director of Biotronik, said: "We have taken a leadership position both in innovation and in offering physicians and their patients the broadest options for individualised therapy, including access to MR scanning."

This comes after the firm launched MRI-compatible Lumax 740 implantable cardiac defibrillators and cardiac resynchronisation therapy defibrillators earlier this month.